PRINCETON, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, will release third quarter 2025 financial results on Thursday, October 30, 2025, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to part ...

Core Points - Ventripoint Diagnostics Ltd. announced the issuance of an additional $297,000 of unsecured convertible debenture units, bringing the total to $567,000 for the Offering [1][2] - Each unit consists of a $1,000 unsecured convertible debenture and 9,000 common share purchase warrants [1] - The conversion price for the debentures is set at $0.11 per common share, with warrants exercisable at $0.14 until December 31, 2027 [2] Financial Details - The debentures mature on December 31, 2027, and carry a 10% interest rate, payable semi-annually [3] - The Corporation paid a total of $320 in cash finder's fees and issued 2,286 finder's warrants, which can be exercised at $0.11 per share for 18 months [4] - Proceeds from the Offering will be used for operational costs, sales and marketing, and general working capital [5] Regulatory and Market Information - All securities issued are subject to a four-month hold period and require approval from the TSXV [6] - The securities will not be registered under the U.S. Securities Act of 1933 and cannot be sold in the U.S. without proper registration or exemption [7] Company Overview - Ventripoint is a leader in applying AI to echocardiography, with its VMS+ products providing accurate cardiac measurements comparable to MRI [8] - The technology is versatile and compatible with all ultrasound systems, supported by regulatory approvals in the U.S., Europe, and Canada [9]

(Photo by Matthias Balk/picture alliance via Getty Images)dpa/picture alliance via Getty ImagesDeal OverviewOn October 2, 2025, reports surfaced that Siemens AG (US OTC: SIEGY ADR, $142.89; Market Capitalization: $228.6 billion) is actively evaluating a potential spin-off of a substantial portion of its majority stake in Siemens Healthineers (US OTC: SMMNY ADR, $27.31; Market Capitalization: $61.6 billion), its publicly listed medical technology subsidiary.The potential spin-off is part of Siemens’s broader ...

Core Insights - Abbott Laboratories (NYSE:ABT) is recognized as a reliable healthcare company, with positive remarks from Jim Cramer, who described the stock as "terrific" and noted the company's long-standing presence in his investment trust [1] Financial Performance - Abbott Labs reported mixed results in their latest earnings update, which was perceived as disappointing in an otherwise positive market [1] - The company tightened its full-year earnings guidance instead of raising it, indicating a cautious outlook [1] - Abbott also lowered its organic sales growth forecast and operating margin outlook, suggesting potential challenges ahead [1]

Core Viewpoint - Johnson & Johnson (J&J) plans to separate its orthopaedics division, DePuy Synthes, from the main company within the next 18 to 24 months, following strong third-quarter results that exceeded Wall Street expectations [1][5]. Financial Performance - J&J reported quarterly revenue of $24 billion for Q3, surpassing the average analyst estimate of $23.7 billion [5]. - The company raised the midpoint of its estimated 2025 reported sales guidance by $300 million, bringing the new figure to $93.7 billion [5]. - Despite higher taxes, J&J maintained its adjusted earnings guidance for 2025 [6]. Business Strategy - The separation of the orthopaedics unit is intended to allow it to operate as a standalone entity, potentially becoming the largest in the world, while enabling J&J to focus on higher-growth, higher-margin markets [3]. - J&J is currently evaluating the mechanics of the separation, considering a spinoff as the most complex and resource-intensive option [3]. Leadership Changes - Namal Nawana has been appointed to lead the orthopaedics unit; he is a veteran medical technology executive with prior experience at Alere Inc. and Smith & Nephew Plc [4]. Market Context - The healthcare sector faces uncertainty due to potential tariff pressures from the U.S. government, which may impact pricing strategies across the industry [7]. - Rival drugmakers, including Pfizer Inc. and AstraZeneca Plc, have begun offering discounts in anticipation of tariff changes [7]. Investment Initiatives - J&J pledged to invest $55 billion over the next four years in U.S. manufacturing, research and development, and technology [8]. - The company also announced a $2 billion investment in a manufacturing site in Holly Springs, North Carolina, expected to create around 120 new jobs [8].

Core Viewpoint - Johnson & Johnson is separating its orthopedics business into a standalone company named DePuy Synthes, allowing the company to concentrate on its pharmaceutical and MedTech segments [1][2]. Group 1: Business Separation - The orthopedics business generated over $9 billion in sales last year, and the split is intended to enable J&J to focus on higher-growth areas [2]. - The separation is expected to be completed within the next 18 to 24 months [2]. Group 2: Leadership and Market Performance - Namal Nawana, former CEO of Smith & Nephew, will lead the new orthopedics company [2]. - J&J reported better-than-expected third-quarter earnings and reaffirmed its adjusted earnings guidance for the year, although shares slipped more than $2 to $188.74 in premarket trading [3]. - J&J's shares have increased over 30% so far this year [3].

GE HealthCare's digital strategy is cloud-first, AI-powered, and software-enabled—building intelligent hardware as well as standalone applications and software solutions to support better care delivery and enhanced patient outcomes. CareIntellect for Perinatal is part of the CareIntellect family of applications which use a common, cloud-first infrastructure running on the Amazon Web Services (AWS) cloud. Customers who adopt CareIntellect applications can quickly and easily install new capabilities and appli ...

Strengthens focus of Johnson & Johnson as an innovation powerhouse and accelerates the portfolio shift of its MedTech Segment to higher-growth and higher-margin markets Standalone orthopaedics business would operate as DePuy Synthes and be the largest, most comprehensive orthopaedics-focused company in the world Namal Nawana appointed to serve as Worldwide President of DePuy Synthes NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (the "Company†) (NYSE: JNJ) today announced the Company's intent to ...

Market Overview - U.S. equity markets continued to rise in Q3, with the Russell 1000 Growth Index increasing by 10.5% and achieving 24 new all-time highs [3] - The S&P 500 rose by 8.1%, the Nasdaq 100 advanced by 11.2%, and the Dow Jones Industrial Average increased by 5.2% [3] - The rally was largely driven by significant infrastructure investments in the AI sector, including a $90 billion plan announced by President Trump and various multi-billion dollar partnerships among major AI companies [3] Economic Impact - Deutsche Bank estimates that tech spending, primarily in AI, will contribute approximately 1-1.5 percentage points to U.S. GDP growth in 2025 [3] - The U.S. government has been running around $2 trillion in fiscal deficits for the first 11 months of FY-2025, which, along with easing monetary policy, has supported equity market performance [3][6] Monetary Policy - The Federal Reserve cut the Federal Funds rate by 25 basis points to a range of 4.00%-4.25% in mid-September, with a more accommodative policy outlook for the coming years [6] - The Fed's median projection for the fed funds rate in 2025 has decreased to 3.6% from 3.9% [6] Sector Performance - Ithaka's portfolio underperformed the Russell 1000 Growth Index by 940 basis points in Q3, with stock selection and sector allocation negatively impacting performance [8] - Positive relative returns were generated in the Financial Services sector, while Technology and Consumer Discretionary sectors were the largest sources of underperformance [9] Key Contributors and Detractors - Top contributors included NVIDIA (18.0% return impact), Robinhood Markets (52.9%), and Shopify (28.8%) [10] - Major detractors were ServiceNow (-10.5%), Chipotle Mexican Grill (-24.6%), and Intuitive Surgical (-17.7%) [10] AI Investment Landscape - The AI infrastructure buildout is projected to reach $400 billion to $600 billion in 2025, with U.S. hyperscalers expected to account for $300 billion to $350 billion of this total [18] - The current wave of AI-driven capital expenditures is compared to historical infrastructure projects, indicating a significant shift in technology investment [18] Future Outlook - The ongoing AI buildout may redefine human interaction across various sectors, with companies viewing this as a once-in-a-generation opportunity [18][21] - Early productivity gains from AI implementations have shown efficiency improvements of 20%-50% in key business operations [20]

Core Insights - Medtronic plc (NYSE:MDT) is recognized as one of the Top 15 Growth Stocks for Long-Term Investors [1] - The company is the largest producer of biomedical devices and implantable technologies globally, operating through four main segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes [2] Growth Strategy - Medtronic pursues growth through internal innovation and strategic acquisitions, with a strong focus on research and development (R&D) driving organic expansion [3] - The company has established a significant presence in emerging markets such as China, India, and Africa, which are characterized by large populations and rapidly expanding economies [3] Financial Performance - Revenue from emerging markets has been growing at a double-digit pace, outpacing growth in the United States, which contributes just over half of Medtronic's total revenue [4] - In fiscal Q2 2025, Medtronic recorded $4.2 billion in revenue from US operations and $4.3 billion from international markets [4] Acquisitions and R&D Investment - Since 2021, Medtronic has completed nine tuck-in acquisitions worth over $3.3 billion, reflecting its commitment to expanding capabilities and product offerings [5] - The company consistently spends over $2 billion annually on R&D, which is central to its continuous product innovation and leadership in the medical technology space [5] Dividend Performance - Medtronic has increased its dividend for 48 consecutive years, highlighting its financial stability and shareholder-focused approach [6] - The current quarterly dividend is $0.71 per share, with a dividend yield of 2.98% as of October 12 [6]